William R. Lenderking
William, a clinical psychologist, has over 20 years’ experience in the field of outcomes research, starting with a position as a post-doc at Harvard School of Public Health with the AIDS Clinical Trials Group. During his clinical and pre-clinical training, he spent over three years working on inpatient units with patients with severe psychiatric diagnoses, including patients with schizophrenia. He also held staff positions in the Psychiatry Department at Massachusetts General Hospital progressing to Assistant Clinical Professor at Harvard Medical School, and had an independent clinical practice for 15 years. He was with Pfizer Inc. for 7 years as Director of Worldwide Outcomes Research, primarily supporting the Neurosciences development portfolio and the Depression teams, but he also worked extensively in Infectious Diseases. As the HEOR representative on the Depression team, he developed the daily version of the QIDS, and conducted two studies using the scale to detect early depression response. At UBC, he was the Project Director for the Cognition Initiative, a multi-sponsor consortium project with the Critical Path Institute to develop a new measure of the earliest symptoms of mild cognitive impairment. He has also completed a number of projects in oncology as Principal Investigator, including a PRO landscape review, a global value dossier for non-small cell lung cancer, and projects in prostate cancer and multiple myeloma.
Prior to joining Pfizer, William was a consultant to the pharmaceutical industry with Phase V Technologies, Inc., and Abt Associates. He has been developing questionnaires for over 20 years, and has over 50 peer-reviewed articles, chapters, and published letters, in journals such as New England Journal of Medicine, Annals of Internal Medicine, Journal of General Internal Medicine, Public Health Reports, Journal of Trauma, Journal of Personality Assessment, Value in Health, Pharmacoeconomics, and Quality of Life Research. William co-chaired the ISOQOL Mid-year symposium in Boston, 2004, and the conference proceedings were published as a book co-edited with Dennis Revicki, titled Advancing Health Outcomes Research Methods and Clinical Applications. He has served as Associate Editor of Quality of Life Research (2000-2003), and was co-editor of Value in Health from 1999-2008. In this capacity, he published several editorials, including one on the translation process, and he has participated in the translation of a number of instruments for multi-national clinical trials.
William contributed to the Pfizer and ISOQOL responses to the FDA PRO draft guidance issued in February 2006, co-led two ISOQOL symposia on the draft guidance and a contributed workshop, and was part of the ISPOR Task Force that published a white paper describing validation issues for e-PRO technology (Coons et al, 2009). He was the Secretary/Treasurer of the International Society of Quality of Life Research (ISOQOL) from 2011-2014.